Oracle Runs

Oracle findings and outcome history for Phase 2b Study of GSK4532990 in Adults With NASH (NCT05583344).

Runs

Findings

Latest Run

Apr 6, 2026, 2:08 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial (HORIZON, NCT05583344) is active not recruiting with primary completion Jan 2026; no results posted on ClinicalTrials.gov or announced by GSK. GSK pipeline docs list it as ongoing without outcome data or interpretation. No public readout exists to classify as positive or negative.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:20 PM

ClinicalTrialsclinicaltrials.gov

Phase 2b Study of GSK4532990 in Adults With NASH

Status: Active, not recruiting. Primary completion: 2026-01-31 (estimated). No results posted. Study completion estimated 2027-04. IPD available 6 months after primary endpoint results publication.

Sponsorgsk.comFeb 3, 2026, 12:00 AM

GSK FY 2025 Pipeline Assets and Clinical Trials Report

GSK4532990 (HORIZON NCT05583344) listed in Phase IIb for MASH/NASH with advanced fibrosis. Key endpoints match trial (fibrosis improvement and NASH resolution at Week 52). No results or data reported; described as ongoing.

NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM

ClinicalTrialsclinicaltrials.govMar 24, 2026, 12:00 AM

Study Details | NCT05583344 | ClinicalTrials.gov

ClinicalTrials.gov lists active not recruiting; primary completion 2026-01-31; hasResults=false on the latest posted update.

NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. The study record still shows Active, not recruiting on ClinicalTrials.gov, GSK still lists HORIZON/NCT05583344 as an ongoing Phase II asset, and GSK’s AASLD 2025 materials mention only PK-PD modeling for HORIZON rather than topline efficacy. That is insufficient to call the trial positive or negative.

Found Apr 3, 2026, 4:04 PMReviewed Apr 3, 2026, 4:47 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT05583344 | Phase 2b Study of GSK4532990 in Adults With NASH | ClinicalTrials.gov

ClinicalTrials.gov lists NCT05583344 as a Phase 2b study of GSK4532990 in adults with NASH; the record is still active rather than a posted results readout.

Sponsorgsk.com

Q4 2025 pipeline assets and clinical trials report

GSK’s FY2025 pipeline report still lists GSK4532990/HORIZON (NCT05583344) under Phase II, consistent with an ongoing program and not a disclosed positive/negative Phase 2b outcome.

Sponsorgsk.com

GSK presents data from its advancing liver pipeline at AASLD 2025 | GSK

For GSK4532990, GSK highlighted an AASLD 2025 poster on PK-PD modeling supporting dosing in the HORIZON phase 2b study, not a trial-specific efficacy topline readout.

NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. ClinicalTrials.gov still showed the study active/not recruiting with a Feb 10, 2026 update, and GSK’s own pipeline materials continued to list HORIZON data as anticipated in 2026+ / still in Phase II/III development rather than reporting outcomes.

Found Apr 1, 2026, 6:47 PMReviewed Apr 1, 2026, 7:04 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT05583344 | Phase 2b Study of GSK4532990 in Adults With NASH

ClinicalTrials.gov entry for NCT05583344 remained active/not recruiting, with an update dated 2026-02-10; no posted results or interpretive efficacy readout were identified.

Sponsorgsk.com

Pipeline assets and clinical trials append

GSK lists NCT05583344 (HORIZON) on page 91 as Phase IIb with 'Data anticipated: 2026+' rather than reported results.

Sponsorgsk.com

GSK Annual Report 2025

GSK’s 2025 annual report still places GSK4532990 for MASH 'in Phase II/III study,' indicating ongoing development and no clear public Phase 2b outcome disclosure.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.